Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - capsule polvere per inalazione - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.080 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - capsule polvere per inalazione - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.160 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - capsule polvere per inalazione - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.320 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika

Європейський Союз - італійська - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - asma - farmaci per le malattie respiratorie ostruttive, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Європейський Союз - італійська - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - asma - farmaci per le malattie respiratorie ostruttive, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Європейський Союз - італійська - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - asma - farmaci per le malattie respiratorie ostruttive, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Європейський Союз - італійська - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asma - farmaci per le malattie respiratorie ostruttive, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

bausch & lomb-iom s.p.a. - carteololo - carteololo

Європейський Союз - італійська - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromuro, vilanterol trifenatate - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - anoro ellipta è indicato come un broncodilatatore di mantenimento di trattamento per alleviare i sintomi in pazienti adulti con malattia polmonare ostruttiva cronica (bpco).

Європейський Союз - італійська - EMA (European Medicines Agency)

novartis europharm ltd - glycopyrronium bromuro - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - enurev breezhaler è indicato come trattamento broncodilatatore di mantenimento per alleviare i sintomi nei pazienti adulti con malattia polmonare ostruttiva cronica (bpco).